
Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) – Analysts at Sidoti boosted their FY2026 earnings per share (EPS) estimates for shares of Harvard Bioscience in a research report issued on Wednesday, November 11th. Sidoti analyst J. Sidoti now forecasts that the medical instruments supplier will post earnings of ($2.37) per share for the year, up from their previous estimate of ($2.44). The consensus estimate for Harvard Bioscience’s current full-year earnings is ($2.44) per share.
Several other equities analysts have also recently issued reports on HBIO. Benchmark boosted their target price on shares of Harvard Bioscience from $6.00 to $7.50 and gave the company a “speculative buy” rating in a research note on Wednesday, August 12th. Zacks Research began coverage on Harvard Bioscience in a research report on Tuesday, November 3rd. They set a “hold” rating on the stock. Weiss Ratings upgraded shares of Harvard Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 9th. StoneX lowered Harvard Bioscience from a “speculative buy” rating to a “hold” rating in a research note on Wednesday, November 11th. Finally, Stonex Financial cut Harvard Bioscience from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 11th. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Harvard Bioscience has an average rating of “Hold” and a consensus price target of $6.75.
Check Out Our Latest Stock Analysis on HBIO
Harvard Bioscience Trading Down 3.6%
Shares of HBIO stock opened at $8.68 on Friday. Harvard Bioscience has a 52-week low of $4.00 and a 52-week high of $10.20. The business has a 50-day simple moving average of $8.41 and a 200-day simple moving average of $6.66. The company has a debt-to-equity ratio of 7.28, a current ratio of 1.76 and a quick ratio of 0.86.
Harvard Bioscience (NASDAQ:HBIO – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The medical instruments supplier reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.27. Harvard Bioscience had a negative net margin of 13.20% and a negative return on equity of 43.94%. The business had revenue of $22.20 million during the quarter, compared to analysts’ expectations of $21.80 million.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Harvard Bioscience stock. Citadel Advisors LLC acquired a new stake in Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 13,251 shares of the medical instruments supplier’s stock, valued at approximately $81,000. Citadel Advisors LLC owned approximately 0.29% of Harvard Bioscience at the end of the most recent quarter. Hedge funds and other institutional investors own 80.87% of the company’s stock.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc. develops, manufactures and sells scientific instruments and equipment used in life science research. Its products support work in areas such as physiology, electrophysiology and preclinical research, and are used by academic and government institutions, biotechnology and pharmaceutical companies, and contract research organizations. The company’s offerings include laboratory instruments, equipment and related consumables, including systems for measuring biological activity and studying tissues, organs and cells.
Featured Stories
- Five stocks we like better than Harvard Bioscience
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
